Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The efficacy of PRRT has been demonstrated in patients with well differentiated NETS. The NETTER-01 study demonstrated disease stabilisation or partial response in approximately 80% of patients. However, more studies are needed to identify predictors of response
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Demetriou G
Authors: Demetriou G, Diamantopoulos L, Devakumar H, Popat R, Koffas A,
Introduction: The traditional treatment regime of somatostatin receptor positive NETs by molecular radiotherapy was based on single radionuclides (e.g. 90Y Dotatate or 177Lu Dotatate), delivered as multiple cycles to allow normal tissue recovery. However a newer practice of alternating tcycles of 177Lu and Y90 Dotatate was implemented at the Christie following introduction of this regime in some European centres. Subsequent follow up studies have indicated that longer overall survival and reduced loss of kidney function is found in patient cohorts treated with combined 177Lu and 90Y regimes to either 177Lu or 90Y alone.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Tipping J
Authors: Page E, Tipping J, Birch E, Hamilton D, Manoharan P,
#550 Predictors of Survival Following Y90 DOTATOC/DOTATATE Therapy
Introduction: Y90-DOTATATE and Y90-DOTATOC are established treatments for patients with advanced neuroendocrine tumours. Outcomes associated with improved survival following therapy are still unclear.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Gilbert T, Mckane G, Banks M, Poston G, Vora J,
Keywords: Y90 DOTATOC/DOTATATE, survival,
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms originating from enterochromaffin cells. NET patients with liver metastases frequently undergo Yttrium-90 (Y90) embolization.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Soltman S, Amin S, Warner R, Weintraub J, Itzkowitz S,
Keywords: neuroendocrine, tumor, biomarker, embolization,
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an increasingly used treatment for GEP -NETs but there is limited data on indications, efficacy and survival.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Khan M, El-Khouly F, Quigley A, Caplin M, Toumpanakis C,
Keywords: neuroendocrine tumor, radionuclides, survival, therapy,